Related scientific articles (all)

Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.

Authors : Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I
Year : 2014
Journal : Oncologist
Volume : 19(4)
Pages : 346-7

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

Authors : de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber Rd, Eidtmann H, Baselga J
Year : 2014
Journal : Lancet Oncol
Volume : 15(10)
Pages : 1137-46

Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.

Authors : Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I
Year : 2014
Journal : Oncologist
Volume : 19(4)
Pages : 348-9

Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.

Authors : Partridge AH, Gelber S, Piccart-Gebhart M, Focant F, Scullion M, Holmes E, Winer EP, Gelber Rd
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(21)
Pages : 2692-8

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

Authors : Martin M, Bonneterre J, Geyer CE, Ito Y, Ro J, Lang I, Kim SB, Germa C, Vermette J, Wang K, Awada A
Year : 2013
Journal : Eur. J. Cancer
Volume : 49(18)
Pages : 3763-72

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

Authors : Awada A, Dirix L, Manso Sanchez L, Xu B, Luu T, Diéras V, Hershman DL, Agrapart V, Ananthakrishnan R, Staroslawska E
Year : 2013
Journal : Ann Oncol
Volume : 24(1)
Pages : 109-16

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer.

Authors : Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart-Gebhart M, Joensuu H, Sotiriou C
Year : 2013
Journal : J. Natl. Cancer Inst.
Volume : 105(13)
Pages : 960-967

Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development

Authors : Vanderbeeken MC, Aftimos P, Awada A
Year : 2013
Journal : Current Breast Cancer Rep
Volume : 5
Pages : 31-41

Luminal breast cancer: from biology to treatment.

Authors : Ignatiadis M, Sotiriou C
Year : 2013
Journal : Nat Rev Clin Oncol
Volume : 10(9)
Pages : 494-506

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Authors : Goldhirsch A, Gelber Rd, Piccart-Gebhart M, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, Mcfadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J
Year : 2013
Journal : Lancet
Volume : 382(9897)
Pages : 1021-8

Impressive response to eribulin in endocrine- and chemotherapy resistant metastatic breast cancer

Authors : Vanderbeeken MC, de Azambuja E
Year : 2013
Journal : Belgian J Medical Oncology
Volume : 7(1)
Pages : 27-30

CD4+ follicular helper T cell infiltration predicts breast cancer survival.

Authors : Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothé F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart-Gebhart M, Sotiriou C, Willard-Gallo K
Year : 2013
Journal : J Clin Invest
Volume : 123(7)
Pages : 2873-92

Why your preferred targeted drugs may become unaffordable.

Authors : Piccart-Gebhart M
Year : 2013
Journal : Cancer Res
Volume : 73(19)
Pages : 5849-51

Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer.

Authors : Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(20)
Pages : 2586-92

Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles.

Authors : Aftimos P, Wiedig M, Langouo Fontsa M, Awada A, Ghanem G, Journe F
Year : 2013
Journal : Int J Oncol
Volume : 43(3)
Pages : 919-26

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.

Authors : Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : PLoS One
Volume : 8(1)
Pages : e53292

Targeting RANKL in breast cancer: bone metastasis and beyond.

Authors : Azim H, Azim HA
Year : 2013
Journal : Expert Rev Anticancer Ther
Volume : 13(2)
Pages : 195-201

Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.

Authors : Saghatchian M, Mook S, Pruneri G, Viale G, Glas AM, Guerin S, Cardoso F, Piccart-Gebhart M, Tursz T, Delaloge S, van t Veer L
Year : 2013
Journal : Breast
Volume : 22(5)
Pages : 682-90

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.

Authors : Azim HA, Michiels S, Zagouri F, Delaloge S, Filipits M, Namer M, Neven P, Symmans WF, Thompson A, André F, Loi S, Swanton C
Year : 2013
Journal : Ann Oncol
Volume : 24(3)
Pages : 647-54

Multigene assays for late recurrence of breast cancer.

Authors : Ignatiadis M
Year : 2013
Journal : Lancet Oncol
Volume : 14(11)
Pages : 1029-30